Discover the future of investment with our analysis on five companies set to dominate 2025. Explore giants revolutionising data, retail investing, satellite connectivity, AI-driven nuclear energy, and semiconductor innovation. As...
Dive into the semiconductor sector to uncover potentially undervalued opportunities among 20 key players, including giants like Taiwan Semiconductor and ASML, and niche innovators such as Impinj and Aehr Test...
Explore how a single drug, Dupixent, might be redefining Sanofi's market valuation. With sales exceeding €10 billion, Dupixent's robust cash flow could underpin Sanofi’s worth, raising questions about whether investors...
In the dynamic realm of biopharma, Vertex Pharmaceuticals holds a commanding position in cystic fibrosis treatment, boasting a market capitalisation over $100 billion. With patent protection on key therapies until...
Large-cap pharmaceuticals are grappling with historically low valuations, with firms like Pfizer and AbbVie trading at single-digit P/E ratios. This gloomy outlook compresses IPO activity and stifles innovation, creating an...
In the tumultuous biotech sector, Moderna emerges as an intriguing contrarian bet with its mRNA platform holding untapped potential. Despite political headwinds and market scepticism, the company's diverse pipeline, including...
Amid remarkable strides in treating rare diseases and the pressing challenges posed by ageing populations, healthcare investment landscapes are being reshaped. Opportunities abound for investors focused on long-term trends, with...
A biotech titan, renowned for its mRNA innovation, might just be undervalued at a price nearly equivalent to its cash reserves. With $2 billion in COVID-19 vaccine revenues and over...
In the evolving landscape of biotech regulation, whispers of change at the FDA signal a potential renaissance. Recent leadership shifts hint at a more innovation-friendly approach, potentially expediting approvals for...
Vertex Pharmaceuticals is quietly establishing itself as a powerhouse, generating over $10 billion in annual revenue. With trailblazing innovations like the CRISPR-based Casgevy and non-opioid Journavx, Vertex is reshaping the...
